On March 24, 2026, Apogee Therapeutics, Inc. entered into an underwriting agreement with Jefferies LLC, TD Securities (USA) LLC, Stifel, Nicolaus & Company, Incorporated, and Guggenheim Securities, LLC, to issue and sell 5,000,000 shares of its common stock at a public offering price of $70.00 per share. The company has also granted the underwriters a 30-day option to purchase up to an additional 750,000 shares at the same price, which was fully exercised on March 25, 2026. The net proceeds from the offering, including the proceeds from the exercised option, are expected to be approximately $377.4 million after deducting underwriting discounts and commissions and estimated offering expenses. This offering is being made pursuant to a shelf registration statement that became effective on August 12, 2024. A final prospectus supplement detailing the terms of the offering was filed with the U.S. Securities and Exchange Commission on March 25, 2026, and the offering is expected to close on March 26, 2026. The underwriting agreement includes indemnification provisions for the underwriters against certain liabilities, including those under the Securities Act of 1933. This capital raise is expected to enhance Apogee's liquidity position and support its operational and strategic initiatives moving forward.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.